TET2 and cancer: These clinical trials (NCT03397173, NCT03433781, and NCT03999723) in myelodysplastic syndrome, acute myeloid leukemia, and others have been focused on investigating the efficacy and safety of oral vitamin C, an activator of TET enzymes, in combination with DNMT inhibitors to potentiate the hypomethylating effect in patients with TET2 mutant cancers.